Limited Success: Third-Line Therapy Yields Modest Responses in Steroid-Refractory aGvHD with GI Involvement
Highlights
Third-line therapy for steroid- and ruxolitinib-refractory acute graft-versus-host disease with gastrointestinal involvement demonstrates limited effectiveness, with only 36% overall response rate at Day 28. More than half of responding patients lost their response within 90 days, highlighting significant durability concerns. The median overall survival was 86 days, though responders showed substantially better outcomes with median OS of 186 days compared to 45 days in non-responders. Infectious complications and aGvHD progression remained the leading causes of mortality, affecting over half of the patient population within three months.
Background
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.